Personalized facial rehabilitation for people with systemic sclerosis
Official title: Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
Run by University Hospital, Strasbourg, France · NCT05177380 · Data updated 2026-11-12
A personalized facial rehabilitation program is being tested to see if it helps adults with facial involvement from systemic sclerosis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg, Bas-Rhin) |
| Status | Recruiting |
| Started | October 13, 2022 |
| Main results expected | November 2029 |
| Study ends | December 2029 |
| Registry record updated | June 8, 2026 |
| Trial ID | NCT05177380 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with systemic sclerosis and facial involvement (MHISS score > 6) who are stable on immunosuppressive/anti-fibrosis therapy and able to consent.
✕Probably not a fit
Patients with no facial involvement progression or those not responsive to rehabilitation may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests a tailored rehabilitation program targeted at facial involvement in adults with systemic sclerosis. Participants receive a customized set of facial exercises and a standard rehabilitation prescription to address functional and aesthetic aspects of facial involvement. The study uses the MHISS score to identify eligible individuals and to track changes over the course of treatment. Immunosuppressive or anti-fibrosis therapies must be stable for at least one month prior to enrollment. The primary aim is to determine whether the personalized program can improve facial function and quality of life compared with baseline care. Recruitment is limited to patients treated at the Strasbourg university hospital in France.
Why it matters
Potential benefit: If successful, patients may experience improved facial function, easier mouth opening, and better quality of life.
How similar studies have gone: Previous work suggests facial rehabilitation can help with functional aspects of facial involvement in systemic sclerosis, though this precise personalized approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 yo * Systemic sclerosis according to the 2013 ACR/EULAR (American College of Rheumatology) classification criteria * Systemic sclerosis with facial involvement defined by a MHISS score \> 6 * Immunosuppressive and/or anti-fibrosis treatment stable for at least 1 month * Subject able to understand the objectives and risks of research and to give informed consent * Subject enrolment in the health insurance scheme Exclusion Criteria: * Pregnancy * Previous participation in a rehabilitation program of facial involvement * Patient under legal protection * Impossibility to give clear information of subject
Where it's running
-
Hôpitaux Universitaire de Strasbourg
Strasbourg, Bas-Rhin, France Recruiting
Study contacts
- Study coordinator: Emmanuel CHATELUS, MD
- Email: emmanuel.chatelus@chru-strasbourg.fr
- Phone: +33 3 88 12 71 40
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can hard gum chewing change your facial appearance?
This study tests whether chewing a standardized hard gum for 4 weeks can produce measurable changes in facial soft tissue in healthy adults aged 20–40.
-
Test of HBM7020 in healthy adults and adults with autoimmune diseases
This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.
-
Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases
This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.
-
Immun4Cure Cohort of Autoimmune Diseases
A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.
-
Nerandomilast for Systemic Sclerosis in Adults
This study tests whether nerandomilast tablets can help adults with systemic sclerosis compared to a placebo.
-
AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis
This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.